Characteristic
N (%) Entire cohort: n=49,361
Mean age, years (SD) 51.9 (12.0)
Male Gender 37,876 (76.7%)
Race Caucasian African American Hispanic Asian Other Unknown 37,224 (75.4%) 7,492 (15.2%) 3,076 (6.2%) 1,078 (2.2%) 468 (1.0%) 23 (0.1%)
Diagnosis at Listing Dilated Myopathy Restrictive Myopathy Hypertrophic Myopathy Prior graft failure CAD Valvular Disease Congenital Other 35,915 (72.8%) 872 (1.8%) 811 (1.6%) 1,077 (2.2%) 7,611 (15.4%) 1,208 (2.5%) 1,030 (2.1%) 96 (0.2%)
Year Transplanted October 1987 – December 2004 January 2005 – September 2018 26,534 (53.8%) 22,827 (46.3%)
Comorbidities Mean BMI, kg/m2 (SD)
26.3 (4.7)
Mean GFR, mL/min/1.73m2 (SD) GFR >90 (CKD stage I) GFR 60-89 (CKD stage II) GFR 45-59 (CKD stage IIIa) GFR 30-44 (CKD stage IIIb) GFR 15-29 (CKD stage IV) GFR <15 (CKD stage V) Unknown 70.0 (25.8) 9,205 (18.7%) 15,838 (32.1%) 9,011 (18.3%) 5,149 (10.4%) 1,129 (2.3%) 167 (0.3%) 8,862 (18.0%)
Diabetes No Yes Unknown 29,925 (60.6%) 8,993 (18.2%) 10,443 (21.2%)
History of smoking No Yes Unknown 12,226 (24.8%) 10,960 (22.2%) 26,175 (53.0%)
Cerebrovascular disease No Yes Unknown 36,909 (74.8%) 1,776 (3.6%) 10,676 (21.6%)
History of Cancer No Yes Unknown 38,331 (77.7%) 269 (0.5%) 10,761 (21.8%)
Infectious Disease Serology HBV Core Antibody Negative Positive Unknown 35,430 (71.8%) 1,622 (3.3%) 12,309 (24.9%)
HCV Serostatus Negative Positive Unknown 39,651 (80.3%) 838 (1.7%) 8,872 (18.0%)
CMV Status Negative Positive Unknown 11,660 (23.6%) 19,493 (39.5%) 18,208 (36.9%)
EBV Serostatus Negative Positive Unknown 3,375 (6.8%) 22,125 (44.8%) 23,861 (48.4%)
Post-Op Complications Stroke Yes No Unknown 676 (1.4%) 38,513 (78.0%) 10,172 (20.6%)
Dialysis Yes No Unknown 2,249 (4.6%) 36,964 (74.9%) 10,148 (20.6%)
Induction Therapy Basiliximab ATG 36,384 (73.7%) 6,113 (12.4%) 7,511 (15.2%)
Maintenance Therapy Calcineurin inhibitor mTOR inhibitor MMF Steroid 43,689 (88.5%) 896 (1.8%) 30,405 (61.6%) 43,171 (87.5%)